In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer’s disease patients

2013 ◽  
Vol 40 (6) ◽  
pp. 921-931 ◽  
Author(s):  
Andrea Varrone ◽  
Patrik Mattsson ◽  
Anton Forsberg ◽  
Akihiro Takano ◽  
Sangram Nag ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
In Vivo Imaging ◽  
Translocator Protein

P2-385: Binding and pharmacokinetic properties of novel 18 F-labeled agents for in vivo imaging of tau pathology in Alzheimer's disease

2010 ◽  
Vol 6 ◽  
pp. S429-S430
Author(s):  
Nobuyuki Okamura ◽  
Shozo Furumoto ◽  
Katsutoshi Furukawa ◽  
Hiroyuki Arai ◽  
Kazuhiko Yanai ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
In Vivo Imaging ◽  
Tau Pathology ◽  
Pharmacokinetic Properties

scholarly journals In vivo Imaging of Glial Activation in Alzheimer's Disease

2018 ◽  
Vol 9 ◽  
Author(s):  
Paul Edison ◽  
Cornelius K. Donat ◽  
Magdalena Sastre
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
In Vivo Imaging ◽  
Glial Activation

scholarly journals In vivo imaging of synaptic loss in Alzheimer’s disease with [18F]UCB-H positron emission tomography

2019 ◽  
Vol 47 (2) ◽  
pp. 390-402 ◽  
Author(s):  
Christine Bastin ◽  
Mohamed Ali Bahri ◽  
François Meyer ◽  
Marine Manard ◽  
Emma Delhaye ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Positron Emission Tomography ◽  
In Vivo Imaging ◽  
Emission Tomography ◽  
Synaptic Loss ◽  
Positron Emission

Binding and safety profile of novel benzoxazole derivative for in vivo imaging of amyloid deposits in Alzheimer's disease

2007 ◽  
Vol 7 (4) ◽  
pp. 393-400 ◽  
Author(s):  
Nobuyuki Okamura ◽  
Shozo Furumoto ◽  
Yoshihito Funaki ◽  
Takahiro Suemoto ◽  
Motohisa Kato ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Safety Profile ◽  
In Vivo Imaging ◽  
Amyloid Deposits

scholarly journals Monitoring protein aggregation and toxicity in Alzheimer’s disease mouse models using in vivo imaging

Methods ◽  
2011 ◽  
Vol 53 (3) ◽  
pp. 201-207 ◽  
Author(s):  
Tara L. Spires-Jones ◽  
Alix de Calignon ◽  
Melanie Meyer-Luehmann ◽  
Brian J. Bacskai ◽  
Bradley T. Hyman
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Protein Aggregation ◽  
Mouse Models ◽  
In Vivo Imaging

P1-284: In vivo imaging of amyloid deposition in Alzheimer's disease using the novel radioligand [18 F] Av-45

2008 ◽  
Vol 4 ◽  
pp. T300-T301
Author(s):  
Paul B. Rosenberg ◽  
Y. Zhou ◽  
A. Kumar ◽  
H.T. Ravert ◽  
J. Brasic ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
In Vivo Imaging ◽  
Amyloid Deposition ◽  
The Novel

scholarly journals Astrocytic TSPO Upregulation Appears Before Microglial TSPO in Alzheimer’s Disease

2020 ◽  
Vol 77 (3) ◽  
pp. 1043-1056 ◽  
Author(s):  
Benjamin B. Tournier ◽  
Stergios Tsartsalis ◽  
Kelly Ceyzériat ◽  
Ben H. Fraser ◽  
Marie-Claude Grégoire ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Glial Cells ◽  
Binding Sites ◽  
Temporal Cortex ◽  
Population Expansion ◽  
Cell Types ◽  
Translocator Protein ◽  
Cellular Origin

Background: In vivo PET/SPECT imaging of neuroinflammation is primarily based on the estimation of the 18 kDa-translocator-protein (TSPO). However, TSPO is expressed by different cell types which complicates the interpretation. Objective: The present study evaluates the cellular origin of TSPO alterations in Alzheimer’s disease (AD). Methods: The TSPO cell origin was evaluated by combining radioactive imaging approaches using the TSPO radiotracer [125I]CLINDE and fluorescence-activated cell sorting, in a rat model of AD (TgF344-AD) and in AD subjects. Results: In the hippocampus of TgF344-AD rats, TSPO overexpression not only concerns glial cells but the increase is visible at 12 and 24 months in astrocytes and only at 24 months in microglia. In the temporal cortex of AD subjects, TSPO upregulation involved only glial cells. However, the mechanism of this upregulation appears different with an increase in the number of TSPO binding sites per cell without cell proliferation in the rat, and a microglial cell population expansion with a constant number of binding sites per cell in human AD. Conclusion: These data indicate an earlier astrocyte intervention than microglia and that TSPO in AD probably is an exclusive marker of glial activity without interference from other TSPO-expressing cells. This observation indicates that the interpretation of TSPO imaging depends on the stage of the pathology, and highlights the particular role of astrocytes.

In vivo imaging of region and cell type specific neocortical neurodegeneration in Alzheimer's disease

2002 ◽  
Vol 109 (5-6) ◽  
pp. 837-855 ◽  
Author(s):  
H. Hampel ◽  
S. J. Teipel ◽  
G. E. Alexander ◽  
O. Pogarell ◽  
S. I. Rapoport ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
In Vivo Imaging ◽  
Cell Type ◽  
Cell Type Specific

In Vivo Imaging of Anticholinesterase Drugs Used in Alzheimer’s Disease

1997 ◽  
pp. 451-456
Author(s):  
B. Tavitian ◽  
S. Pappatà ◽  
F. Branly ◽  
A. Jobert ◽  
A. Dalger ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
In Vivo Imaging
Sign in / Sign up

Export Citation Format

Share Document